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Summary
The interplay between transcription factors, epigenetic modifiers, chromatin remodelers and
miRNAs form the foundation of a complex regulatory network required for establishment and
maintenance of the pluripotent state. Recent work indicates that Myc transcription factors are
essential elements of this regulatory system. Despite numerous reports however, aspects of how
Myc controls self-renewal and pluripotency remain obscure. Here, we review evidence supporting
the placement of Myc as a central regulator of the pluripotent state and discuss possible
mechanisms of action.
Keywords
Myc; pluripotent; self-renewal; reprogramming; embryonic stem cells; induced pluripotent stem
cells
Our understanding of pluripotent cells derived from the inner cell mass of blastocyst-stage
embryos has been guided by the characterization of embryonic stem cells (ESCs). Under the
appropriate culture conditions, ESCs can be maintained as a stable self-renewing population
with developmental potential comparable to that of pluripotent cells in the inner cell mass
(ICM) [1–3]. Recently, ectopic expression of transcription factors including Oct4, Sox2,
Klf4 and c-myc were shown to reprogram somatic cells to a pluripotent state that closely
resemble ESCs. These cells are referred to as induced pluripotent stem cells (iPSCs) [4, 5].
Few differences are evident between ESCs and iPSCs as judged by global gene expression
and epigenetic signatures [6, 7]. Both pluripotent stem cell (PSC) populations can form
embryonic germ layer derivatives in vitro and in vivo and possess long-term self-renewing
capacity in culture [4, 8–10]. These characteristics make PSCs an excellent model for early
embryonic development and a promising source of material for the development of cell
therapies [11, 12]. Since iPSCs can be readily derived from somatic cells, it may be feasible
to generate patient-specific stem cells that can then be used as part of a cell therapy strategy
to cure disease and repair injury. Transplantation of a patient’s cells would offer many
advantages. For example, they would avoid immunological complications associated with
the transplantation of foreign donor cells. Since iPSCs are derived from somatic cells and do
not involve embryonic material, they bypass the ethical concerns associated with use of
ESCs. Before the promise inherent to both ESCs and iPSCs can be fully realized, it is
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critical to fully understand the mechanisms that underpin their establishment and
maintenance. This review will focus on what we currently know about the role of Myc in
maintenance of pluripotent cells and its functions in cellular reprogramming.
Myc: An Introduction
The three major Myc family members, c-myc, N-myc and L-myc have well-established
roles in cell growth, proliferation, cytoskeletal structure, cellular adhesion and motility,
differentiation, and apoptosis [13–17]. Myc factors also have well-established transforming
capacity of primary cells in vitro and they frequently act as oncogenes in tumor development
[17, 18]. The Myc family members share significant protein sequence similarity and are
characterized as belonging to the basic helix-loop-helix family of transcription factors. In
different contexts, Myc can activate or repress target genes by binding to regulatory regions
in a sequence-dependent or independent manner [17, 19–21]. Trans-activation by Myc often
occurs through canonical and non-canonical E-box sequences (CACGTG/CANNTG) [22,
23]. However, their trans-activation potential is fairly weak, in general typically resulting in
only small changes in target gene expression [22, 24, 25].
Myc family-members heterodimerize at E-boxes with their binding partner, Max [26–29].
Recent evidence also suggests that some E-box-independent activities of Myc can be
associated with transcriptional repression, regulation of apoptosis, control of epigenetic
modifications, binding to pre-replicative complexes at replication origins, post-
transcriptionally controlling protein expression and activation of RNA polymerase I and III-
dependent transcription. In these contexts, Myc functions independently of Max [30–37].
Little is known regarding mechanisms of Myc-mediated repression. Perhaps the best-
characterized example involves E-box independent repression of Miz-1 and its targets [31].
In addition to the functions mentioned above, Myc potentially regulates large numbers of
genes. Global studies indicate that c-myc binds both genic and intergenic regions to control
the expression of more than 10% of all genes as well as non-coding (nc) RNAs [19, 22, 38].
Myc: Critical for Embryonic Development?
Deciphering roles for Myc transcription factors in the peri-implantation embryonic stage
from which ESCs are derived has been challenging because they display functional
redundancy and overlapping expression patterns during that timeframe [39, 40]. This is
likely to explain the absence of distinct developmental defects during pre- and peri-
implantation stages of development following knockout of Nor c-myc individually. N-myc
null embryos die at approximately E10.5–12.5, displaying defects in the developing heart,
lung, gut and neural system [41, 42]. c-myc knockout embryos arrest by E10.5, displaying
size reduction in addition to malformations in the developing heart, neural tube, vascular and
hematopoietic systems, as well as defects in the turning of the embryo [43, 44]. Trumpp and
coworkers suggested that the lethality due to c-myc inactivation was primarily due to
placental and hematopoietic deficiencies, as residual N-myc activity could possibly
substitute in other contexts [45].
More recently, we and others have demonstrated that the presence of either c- or N-myc is
essential for early embryonic development [46, 47] and that both are required for ESC
(46,47) and iPSC (46) self-renewal. Myc seems to promote pluripotency at multiple levels.
The first molecular targets shown to be critical for Myc’s role in self-renewal were recently
identified and involve the repression of differentiation genes such as GATA6 and the
activation of miRNAs that control the cell cycle (46). Together, these studies underscore the
importance of c-myc or N-myc in embryonic development at the time of implantation. As L-
myc failed to compensate for c- and N-myc, these studies also reemphasize the differential
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roles held by c-myc and N-myc versus L-myc in embryonic development [46]. It was
previously shown that although L-myc is expressed in multiple organs in the developing
embryo, c-myc and/or N-myc may functionally substitute as L-myc null animals are viable
with no apparent abnormalities at birth [48]. L-myc is also the least tumorigenic of the three
paralogs, and opposes the effect of c-myc with some target genes [29, 49, 50]. Max deletion
is lethal at approximately E5.5, and questions remain about whether N- and c-myc are
functionally redundant in all contexts, particularly with respect to specification of embryonic
germ layer derivatives [51].
Regulation of PSCs: Complex Circuitry
Self-renewal and pluripotency in PSCs are governed by the actions of a complex regulatory
circuit. Signaling molecules such as LIF and BMPs stimulate downstream transcription
factor activity to generate regulatory loops comprised of transcription factors and their
targets – these include additional transcription factors, signaling components and miRNAs
[52–57]. Global studies suggest that constant expression of the fundamental components of
this regulatory network is strictly controlled by perpetuation of feed-forward loops. This
generates a circuit that may be further fine-tuned by the action of miRNAs [55–58]. Protein-
protein interactions that mediate complex formation facilitate the recruitment of additional
regulators to target gene promoters to further expand the circuit [59, 60]. It is generally
thought that maintenance of this network serves to inhibit differentiation while promoting
self-renewal [55, 60–63].
Oct4, Sox2 and Nanog were the first components of the core transcriptional regulatory
circuitry identified using genome-wide location analyses in human and mouse ESCs [55,
63]. These transcription factors are thought to regulate hundreds of target genes in
pluripotent cells, indicative of their pivotal role in pluripotency. Subsequent reports provide
evidence for a larger network consisting of additional transcription factors including Nac1,
Dax1, and Zfp281 [58]. Together, these key transcriptional regulators are thought to
maintain expression of protein products and miRNAs required for maintenance of
pluripotency, while simultaneously imposing a blockade on those that would result in
lineage specification. Although this suggests dual potential of the transcriptional circuitry to
activate and repress target genes to potentiate the pluripotent state, direct evidence for
functional activation or repression of those hundreds of target genes by each central
regulator is mostly lacking [55, 58]. As a transcription factor with mRNA and ncRNA
targets and as a modulator of the epigenome required by many stem cell populations [19, 22,
34, 64], Myc holds unique potential as a key controller of the regulatory processes
mentioned above. Significant effort has therefore been extended into examination of Myc’s
role in the PSC circuit.
Myc: Pleiotropic regulator of the PSC state
Substantial progress has been made to define Myc’s importance in various adult stem cell
and multipotent progenitor populations. In the absence of N-myc, neural progenitors are not
maintained, as proliferation is inhibited while differentiation ensues [65]. N-myc also plays
a similar role in the developing lung where it regulates proliferation to maintain progenitor
cells [66]. The survival of dormant hematopoietic stem cells (HSCs) appears to be Myc-
independent. However, loss of both c- and N-myc affects the survival, proliferation and
differentiation of cycling HSCs [67]. In this case, deletion of both family members was
required to uncover roles for myc. While loss of N-myc leads to no hematopoietic defect, c-
myc deficient HSCs differentiate inappropriately due to modified interactions with the niche
[68]. As c-myc seems to perform a dominant role, this implies some functional hierarchy
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between both family members. In another example, c-myc regulates interactions between
epidermal stem cells and the niche [69].
Several lines of evidence support Myc’s involvement in establishment and maintenance of
PSC populations (Figure 1). Initially, c-myc was implicated in maintenance of mESC self-
renewal where it is a target of LIF/Stat3 signaling [64]. Following LIF withdrawal, Myc
levels decline but if Myc activity is maintained by expression of a stable mutant, ESCs
become LIF-independent. Moreover, expression of a dominant-negative mutant results in
loss of self-renewing capacity [64]. On the other hand, although c- and N-myc single
knockout mESCs are able to self-renew [42, 43, 70], c-myc−/− cells proliferate more slowly
and have defects in vascular and hematopoietic differentiation in vitro. This observation was
recapitulated in vivo using teratoma assays [70]. As expected, inactivation of both c- and N-
myc produced a more deleterious effect. Simultaneous deletion of both family members
resulted in loss of self-renewal and ensuing differentiation [46, 47]. Recent studies have
found that Myc inhibits differentiation to primitive endoderm through repression of GATA6
[46]. Specifically, upon co-deletion of c- and N-myc in iPSCs and ESCs cultured in LIF,
cells primarily differentiate into primitive endoderm at the expense of other lineages [46].
Strikingly, multi-lineage differentiation capacity is lost even when cells are cultured in the
absence of LIF. In support of this, activation of Myc blocks the primitive endoderm
specification in vitro as well as that on the surface of embryoid bodies [46]. Similar to the
aforementioned observations in embryonic development, L-myc is unable to substitute for
the other family members to maintain self-renewal and pluripotency [46]. This is in
opposition to the capacity of L-myc to increase reprogramming efficiency in a manner
similar to c-myc [71].
Contribution to the PSC Regulatory Circuitry
Several studies have identified genome-wide Myc targets in PSCs [46, 58, 73–75]. Although
these target genes are known to be involved in regulation of the cell cycle and metabolism,
this information offered no mechanistic insight into how Myc maintains or establishes the
pluripotent state. Most notably absent from initial global studies were genes with well-
established roles in pluripotency or lineage specification.
The mechanism for how Oct4, Sox2, Klf4 and Nanog regulate pluripotency is based, in part,
on the identification of genes they bind in vivo. For example, binding to active genes
indicates a role in positive regulation while binding to silent genes suggests repression. By
the same type of approach, Oct4, Sox2, Klf4 and Nanog also seem to auto-regulate their
own expression. Similarly, Myc is implicated in cell cycle control, metabolic regulation and
inhibition of differentiation based on target gene identification [46, 55, 58, 63]. However,
instead of being implicated in the Oct4, Sox2, Nanog, and Klf4 circuit, Myc is instead
connected to a distinct regulatory network with Trim28 and Cnot3 [58, 73, 75, 76].
Several studies have shown that Myc binds to the regulatory regions of thousands of genes,
implying possible roles as a more global regulator of transcription [22, 22, 38, 77]. More
than 1600 direct c-myc target genes (www.myccancergene.org) and miRNAs have been
identified in somatic cells and cancer cell lines. These targets have roles in cell cycle
regulation, metabolism, chromatin maintenance, RNA and protein synthesis and processing,
cellular structure and adhesion. Even this is still likely to be an under-estimation of true
numbers of c-myc targets as Amati and colleagues have shown that it may regulate 10–15%
of all genes [22]. This has held true in PSCs where global studies have collectively
identified upwards of 3000 targets [58, 73–75]. Interestingly, Myc is also implicated to
regulate PolII pause-release at ~30% of actively transcribed genes in PSCs through the
recruitment of P-TEFb [78]. In addition to local targets, recent studies have also indicated
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that Myc may also bind to and regulate expansive chromatin domains to functionally
maintain euchromatin [19, 79]. As ESCs are unique in their state of expansive euchromatic
regions, this potential held by Myc could establish its role as a global controller of the
epigenetic state of PSCs (discussed later).
Regulation of the PSC Cell Cycle
The unlimited capacity and rate of PSC proliferation is underscored by their unique cell
cycle structure and regulation. To divide with generation times of approximately 8–12h,
murine PSCs maintain a cell cycle profile with the majority of the population (~60%) in S
phase interspersed by short gap phases [80]. Myc impacts the cell cycle structure in a
multitude of ways and through a number of cell cycle regulators, including cyclins D2, E
and A [58, 73, 75]. Elevated Myc activity accounts for the increased activity of these
regulators and consequently, the cell cycle structure and rapid cell division rates in PSCs
[81]. Furthermore, expression of the CDK inhibitors, p21Cip1, p27Kip1 and INK4 family
members in PSCs is suppressed. Myc is also likely to have a role in regulation of these
genes as it can interfere with their activation [21, 80, 82].
Murine PSCs also appear to cycle independently of mitogenic signaling pathways, much in
the same way as tumor cells. Mechanistically, this seems to be related to the constitutive
hyper-phosphorylation of the retinoblastoma (Rb) tumor suppressor family [80, 83, 83]. Rb
is the regulator of a cell cycle gateway in G1, known as the restriction point, which normally
connects mitogenic signaling pathways to the cell cycle machinery. Inactivation of Rb by
phosphorylation bypasses the restriction point [84], enabling PSCs to cycle in an
unrestrained manner. Also consistent with inactive Rb is the constitutive activation of E2F
transcription factors. This facilitates expression of E2F targets, many of which include
cellular proliferation genes [80, 81]. Both c- and N-myc physically interact with Rb [85],
and in this way Myc could contribute to overcoming Rb induced cell cycle arrest [86].
The aforementioned characteristics are hallmarks of the unique PSC cell cycle profile that
facilitates long-term proliferation and possibly imposes differentiation blockades. Although
not yet formally proven, these cell cycle properties are likely to be associated with
mechanisms underpinning pluripotency.
With the collapse of c-myc levels on PSC differentiation, there is a reduction in expression
of regulatory cyclins and upregulation of the cell cycle inhibitors p21Cip1and p27Kip1. This
results in decreased CDK activity, effectively activating Rb and establishing cell cycle
regulated activities [80, 81]. Significant restructuring of the cell cycle occurs so that the
proportion of cells in G1 increases to >40% and the proportion of S-phase cells is reduced.
The end result is a profile and generation time that is similar to that observed in many
somatic cell types [80]. Therefore, Myc function is likely to be at the center of this
regulatory network that maintains the characteristic PSC cell cycle.
Regulation of miRNAs
miRNAs add another layer of complexity to the regulation of pluripotent cells by fine-tuning
gene expression [56, 87, 88]. Myc-regulated miRNAs in PSCs include the miR-17-92
cluster, members of the 290 family, and miRs-141, 200, 302, 338, 429 [46, 89, 90]. Through
regulation of these miRNAs, Myc’s reach may expand to a multitude of other targets to
affect the PSC state. In support of this, several Myc-regulated miRNAs have established
roles in self-renewal [89]. Indeed, deletion of c- and N-myc in PSCs results in
downregulation of members of the miR-17-92 cluster. Upon Myc deletion and
downregulation of the miRNA cluster, remodelling of the cell cycle occurs concomitant with
differentiation [46]. This cluster may further extend Myc’s control over PSC proliferation
Smith and Dalton Page 5













through inhibiting cell cycle controllers such as p21, Rb2 and cyclin D1, which are regulated
targets of the cluster [46, 91, 92].
The other core PSC regulators, Oct4, Sox2, and Nanog also regulate miRNAs, thereby
refining gene expression in PSCs [56]. In fact, two groups of miRNA promoters with
opposing function are directly bound by Oct4, Sox2, or Nanog in ESCs. The first group
includes miRNAs found by Chen and colleagues who identified 14 unique miRNAs
including members of the miR-290 and miR-302 families by comparing expression levels of
miRNAs in mESCs, embryoid bodies and somatic cells [93]. Notably, the miR-290 family is
one in which the Oct/Nanog/Sox2 and Myc circuits intersect. Judson et al. highlighted the
significance of this cluster in establishment of pluripotency by showing that in the absence
of exogenous Myc, expression of members of the cluster increases the efficiency of
reprogramming to iPSCs by Oct4, Sox2 and Klf4 [94]. The second group of miRNA genes
bound by Oct4, Sox2 and Nanog are also bound by polycomb-group proteins. These
miRNAs are thought to be repressed targets and are induced upon differentiation [56]. One
such repressed miRNA is Let-7. The Oct4/Sox2/Nanog and Myc circuits may converge on
this miRNA to impede its expression in PSCs [56, 95]. Upon differentiation, Let-7 may also
contribute to the decline in Myc levels since Myc is a bona fide Let-7 target [95].
Numerous additional miRNAs are also repressed by Myc. These include miRs-15a, 26a, 34a
and 150 [96]. Many of these miRNAs are tumor suppressors through which Myc repression
contributes to tumorigenesis [96]. Several Myc-repressed miRNAs are involved in
promoting differentiation, while others oppose Myc directed PSC maintenance functions.
For instance, miR-26a is involved in muscle differentiation, while members of the miR-15a
cluster may block S-phase entry since a number of cell cycle regulators such as CDK6 are
direct targets [97]. Thus Myc repression of these miRNAs may further contribute to
pluripotency establishment and maintenance.
Myc’s control of the PSC Epigenetic State
Chromatin organization and epigenetic regulation are generally thought to be important
determinants of developmental potency. One striking feature about PSCs is their open
chromatin structure with large regions of transcriptionally-active euchromatin [98–100]. It is
often argued that the euchromatic state allows for many types of genes to be expressed,
consistent with the general developmental plasticity of PSCs. Although it is difficult to
demonstrate this directly, many pieces of evidence indicate that factors important for
pluripotency are also involved in the epigenetic status of PSCs. Nanog and Oct4 for
example, interact with epigenetic regulators such as the histone demethylase LSD1 and the
Swi/Snf family member, Smarca4 [60]. Such interactions directly regulate histone
methylation status and may mediate target gene accessibility by recruiting the esBAF
chromatin-remodeling complex [101].
c-myc could also modulate chromatin state in PSCs, since several histone-modifying and
Swi/Snf chromatin remodeling factors are c-myc transcriptional targets [58, 74]. Myc is also
known to recruit a variety of epigenetic factors to target genes including DNA
methyltransferases, histone-modifying enzymes and components of the chromatin
remodeling machinery [102–104]. As Myc interacting partners include chromatin
remodeling components and histone acetylases and deacetylases [79, 105–107], it is likely to
globally influence chromatin state. Myc is also able to recruit various other HAT containing
complexes including CREB binding protein, p300 and TRRAP, components of histone
acetyltransferase complexes GCN5 and TIP60 [108, 109]. Recruitment of TRRAP
complexes also implicates Myc in chromatin remodeling by members of the ATP dependent
helicase complexes TIP48/TIP49 [105, 110].
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In addition to acetylated lysine residues on histone H3 and H4, other histone marks such as
trimethylation of lysine 4 of histone H3 (H3K4me3) are also associated with transcriptional
activity. This modification is also abundant in PSCs [98, 99, 111]. Aside from genes
containing these active marks, regulatory regions of certain developmental factors including
Sox and Pax family members exist in a poised state. They contain bivalent domains
containing both active H3K4me3 and repressive H3K27me3. These genomic regions are
thus primed for activation upon receipt of the appropriate specification stimulus [112, 113].
A significant proportion of these genes are also marked by H3K27me3 establishing
polycomb proteins as well as the core regulatory factors in this regulation [55, 61, 112].
E-boxes located around regions of H3K4 trimethylation are thought to serve as high affinity
c-myc binding sites [114]. In ESCs, c-myc’s binding sites significantly overlap with
H3K4me3 [58], supporting Myc’s relationship with the unique PSC epigenetic state.
Intriguingly, Myc also interacts with, and inhibits H3K4 demethylases of the Lid/Jarid1
family [37]. This is one possible mechanism by which Myc may be involved in fine-tuning
of the expression of genes involved in maintaining self-renewal.
Myc binding is also inversely associated with the heterochromatin associated H3K27me3
mark [58]. This goes along with the finding of few overlapping sites within genome wide
maps of Myc and polycomb repressive complex 2 that mediates H3K27 methylation [74].
Although Myc binding correlates with the presence of certain epigenetic marks [102, 114], it
remains unclear whether Myc establishes these marks or is recruited as a consequence of
them.
Histone modifications associated with pluripotency change dramatically during
differentiation and coincide with decreased Myc activity. Activating marks such as
H3K4me3 decrease and those associated with repression, such as H3K9me3 and
H3K27me3, become more prevalent. Similarly, repressive marks are concurrently removed
from genes that are required for lineage specification. Altogether, this results in more
compacted heterochromatin and a more repressive gene expression signature. Promoters of
the important pluripotency factors Oct4 and Nanog also undergo DNA methylation to
impede active transcription [62, 98, 99, 115]. It will be important to establish if Myc is
involved specifically in regulation of DNA demethylation of pluripotency genes, via AID-
dependent or independent mechanisms.
Myc: At the Center of Reprogramming
The regulatory functions assigned to Myc so far, firmly establish it as being critical for
maintenance of pluripotency. Myc is also one of the original four factors used in the
reprogramming of somatic cells to the pluripotent state [4] (Figure 2). Significant effort has
gone into delineating the function of Myc in the dedifferentiation process. Myc has well-
established roles as an inhibitor of differentiation [116], and blockage of endoderm
transcriptional programs [46] may be one mechanism by which Myc supports the
dedifferentiation process. Another role for Myc in pluripotency establishment could be to
facilitate access of the other reprogramming factors to target loci. This would involve
recruiting chromatin modifiers such as histone acetyltransferases or histone/DNA
demethylases [4, 75]. Remodeling of gene expression patterns during early reprogramming
is likely to be dependent on Myc’s ability to impose global epigenetic change. Recent
studies support this model and indicate that c-myc is required to extinguish fibroblast-
specific genes during the early stages of reprogramming [117]. This is supported by
experiments showing that the histone deacetylase inhibitor, valproic acid, can substitute for
Myc in iPSC generation [118]. Other compounds that modulate the DNA or chromatin
status, such as BIX01294 and azacytidine also affect reprogramming efficiency [119, 120].
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These observations again highlight the importance of epigenetic regulation in the
establishment and maintenance of the pluripotent state.
The catalytic subunit of telomerase, TERT, is a transcriptional target of Myc and so it is
likely that PSCs maintain telomeric length by high TERT activity [5, 121]. This is similar to
the situation in immortalized cancer cells where increased Myc activity is associated with a
coinciding increase in telomerase activity [122, 122, 123]. Elevated TERT expression is
another key event associated with the establishment of iPSCs [5, 121]. Regulation of
telomerase activity is likely to be another Myc-dependent event during reprogramming.
Another likely role for Myc in reprogramming process involves cell cycle progression. A
number of reports clearly indicate a direct link between a cell’s proliferative capacity and its
capacity for reprogramming (Table 1) [124, 125]. Myc has long been associated with
regulation of cellular division. In somatic cells, exogenous c-myc expression promotes entry
from quiescence into the cell cycle. Myc overexpression often results in transformation and
in many cases, accelerated progression through the G1 phase [126–128]. In extreme cases,
such as in breast cancer cells with elevated cyclin E expression, this leads to a cell cycle
profile more similar to that of PSCs. Additional reports link Myc’s role in cell cycle control
to reprogramming. For example, inhibition of the Cdk inhibitor p21Cip1 and its upstream
regulator, p53, accelerates reprogramming [129, 130]. In this scenario, Myc could inhibit the
Cip1 gene at the transcriptional level or post-transcriptionally through regulation of miRNAs
[131–133]. Myc may therefore be the link between cell cycle control and establishment and
maintenance of PSCs. Indeed, cell cycle remodeling occurs in a stepwise fashion during
reprogramming and partially reprogrammed cells have a profile intermediate between
somatic cells and iPSCs [134].
Yet another mechanism by which Myc impact reprogramming is through DNA replication.
c-myc regulates DNA replication by increasing activity at replication forks [30]. During the
expanded S-phase, progressive displacement of repressive factors and exposure to other
reprogramming factors may facilitate the genome-wide remodeling of transcriptional
programs.
Reprogramming has now been achieved without exogenous Myc. For example,
reprogramming has been achieved using Lin28 and Nanog in place of Myc [135]. It is likely
however, that Myc is still critical under these conditions since endogenous Myc is present in
all cell types. The function of Nanog in maintaining pluripotency was previously discussed
and interestingly enough, Nanog was recently implicated as a low affinity c-myc target in
mESCs [136]. Further assessments are required to determine if this is a functionally relevant
interaction. It should also be mentioned that Myc is a Lin28 target [58]. Lin28 is a RNA
binding protein that possibly stabilizes the transcripts [137] of key reprogramming factors. If
Lin28 acts to stabilize Myc transcripts, this could indirectly propagate Myc-Lin28 function
through somewhat of a feed-forward mechanism. In sum, the data discussed here illustrate
the profound role of Myc in the establishment and maintenance of PSCs.
Myc: A Therapeutic Impediment?
PSCs share many common properties with cancer cells including senescence escape and
immortality. However, unlike stem cell populations which are under strict biological
constraints, tumors result when such control has gone awry. Combinations of the following
processes are common in cancers: ectopic growth, unlimited proliferation, differentiation
inhibition, and escape from apoptotic control [18,138, 139]. Not surprisingly, Myc has been
linked to promoting such processes in normal stem cells [46, 67, 68]. Therefore, it is easily
envisioned that deregulation of Myc is tightly linked to aberrations in these functions in
cellular transformation.
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Tumors are phenotypically variable and this depends on the cell of origin [140]. The
tumorigenic capacity of iPSCs (and ESCs) is exemplified by the formation of tumors upon
injection into immunodeficient recipients. These teratomas, discombobulated masses of
cells, contain cellular derivatives of the embryonic germ layers, and demonstrate the
differentiation potential of PSCs [2, 141]. Other malignancies consist primarily of poorly
differentiated cells. This is often the case with cancers of the blood, which is normally
repopulated by the rapidly dividing transit amplifying cells [140, 142].
Interestingly, the recent advances in iPSC generation, where Myc promotes reversion to a
more primitive undifferentiated state provides indirect evidence for Myc’s capacity to
generate tumors primarily consisting of undifferentiated cells. Reprogramming can be
viewed as similar to a transformation process. However, tumors are not the primary result as
other reprogramming factors balance Myc activities to lend control and pluripotency
specification. Specifically, Klf4 balances Myc promoted proliferation though regulation of
cell cycle inhibitors which are normally inhibited by Myc [143]. Oct4 and Sox2 (and Nanog)
function to direct the activation of pluripotency genes and repression of lineage targets as
discussed previously [57].
Transformation may occur in differentiated cell types to generate cells that have regained
some self-renewal capacity. There is also evidence that some cancers originate from rogue
populations of stem cells that have overridden biological checks [140]. Such cancer stem
cells may arise from normal stem cells accumulating genetic errors leading to their
transformation. A genetic insult to result in amplified Myc expression could be the driving
force behind such transformation. Indeed, Myc is a contributing factor in maintenance of
some cancer stem cell populations, as is the case with hepatocellular carcinoma and glioma
cancer stem cells [144, 145].
Any slight perturbations in Myc expression can have disastrous results in biomedical
applications, as evidenced by tumors that develop in 20% of mice generated from iPSCs [9].
Reactivation of the Myc transgene was observed in mice in which the tumors arose, and was
the likely driving force of the resultant tumors. Similarly, the transplantation of any
undifferentiated PSCs, or differentiated derivatives that display even slight elevation of Myc
could potentially have disastrous consequences for recipient patients. However, as
mentioned previously Myc is a necessary factor for maintenance of fundamental PSC
characteristics, therefore complete inactivation of Myc will not be suitable even if the aim is
to attenuate cancer risk. What is encouraging though is that Myc-dependent tumors regress
with inactivation of Myc [146, 147]. This suggests that PSC cell therapy is feasible. This
will likely require careful monitoring of Myc levels in cells intended for therapeutic use, and
avoiding the use of exogenous Myc under any circumstance, as even small amounts are
likely to skew the delicate balance.
Future Perspective
Myc is a well-established regulator of transcription but much still remains unanswered in
relation to how it maintains PSCs. A full understanding of Myc’s function will be significant
for development of therapeutics derived from PSCs. Although studies of Myc in
maintenance of self-renewal and pluripotency have provided some insight into their roles in
peri-implantation development, further studies on each family member are required. Key
questions that remain include: what is the phenotype of the triple knockout during the pre-/
peri-implantation period? Are precise levels of c- or N-myc required during this period or
will a certain threshold of total Myc suffice? What is the function, if any, of L-myc in the
choice between self-renewal and differentiation? How is each family member regulated at
the transcriptional, post-transcriptional and translational level? What proteins are present in
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Myc complexes, and how are these interactions mediated? How does N-myc redundancy
account for the placental recovery in the c-myc null background? Furthermore, instances
where each member has a specific role in specification of embryonic germ layers and their
immediate derivatives is feasible, and requires further investigation.
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Myc: Critical for Embryonic development
• c-myc and N-myc are required for embryonic development prior to implantation
• L-myc cannot functionally substitute for c- and N-myc.
Regulation of PSCs: Complex Circuitry
• Control of the PSC state is complex and involves the coordination and
functional interaction of key regulators.
• Myc collaborates with other key core PSC regulators to maintain the pluripotent
state.
Myc: Pleiotropic regulator of the PSC state
• Throughout the genome, Myc binds genic and intergenic regions to regulate the
expression of thousands of genes and ncRNAs.
• It is a key regulator of the PSC cell cycle.
• Recent evidence has defined its role as a regulator of the epigenome.
• Due to its control of DNA replication, it facilitates resetting of the epigenome to
establish and sustain pluripotency.
• It maintains telomere lengths through promoting expression of telomerase.
Myc: A Therapeutic Impediment
• Careful monitoring of Myc levels is essential for any PSC derived therapeutic.
• Exogenous activation of Myc expression is ill-advised for stem cell therapies.
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Figure 1. Roles for Myc in maintaining PSCs
Myc regulates establishment and maintenance of pluripotency using diverse mechanisms.
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Figure 2. Myc participates in many aspects of the multistep process to reprogram somatic cells to
the pluripotent state
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Table 1
iPSC generation in the presence and absence of Myc.
Reprogramming factors Cell type Reference
iPSC generation with Myc
OKSM Mouse fibroblasts [4, 9, 148]
Mouse gastric epithelial cells [149]
Mouse hepatocytes [149]
Mouse B-lymphocytes [150]
Mouse neural stem/progenitor cells [151, 152]
Mouse pancreatic beta-cells [153]
Human fibroblasts [5][154]
Human bone marrow mesenchymal cells [155]
Human keratinocytes [156]
Human adipose stem cells [157]
Human cord blood stem cells [158]
Human blood progenitor cells [159]
Marmoset fibroblasts [161][162]
Rat primary ear fibroblasts [162]
Rat bone marrow cells [162]
Pig fetal fibroblasts [163]
Dog embryonic fibroblasts [164]
Rabbit stomach and liver cells [165]
OKM Mouse neural stem cells [151, 152]
OMS Mouse neural stem cells [152]
OM Mouse neural stem cells [152]
iPSC generation without Myc
OSKLN Human aortic vascular smooth muscle cells [166]
OSLN Human fibroblasts [167]
Human cord blood endothelial cells [168]
OKS Mouse embryonic fibroblasts [169, 170]
Mouse hepatocytes[118] [149]
Mouse neural stem cells [152]
Human keratinocytes [156]
Human adipose stem cells [171]
Human cord blood stem cells [158]
OKS (valproic acid) Human fibroblasts [172]
OKN Human fibroblasts [167]
OKL Human fibroblasts [167]
OK Mouse neural stem cells [152]
OS (valproic acid) Human dermal fibroblasts [118]
Human cord blood stem cells [158]
O Mouse neural stem cells [173]
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O:Oct4, S:Sox2, K:Klf4, M:Myc, N:Nanog
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